Enhanced General Purpose Centrifuge Product Line Increases Capacity and Flexibility
New enhanced general purpose centrifuge product line offers clinical and life science researchers the ability to spin more samples in a single run while maximizing critical lab space.
The Thermo Scientific general purpose centrifuges feature increased capacity and flexibility with rotor innovations including the new Thermo Scientific TX-1000 rotor, which is the only rotor on the market that employs a 4-L capacity in a traditional 3-L footprint. In addition, the new Thermo Scientific MicroClick 30 x 2 rotor offers a 30-place capacity for microtube and nucleic acid spin columns, and is ideal for molecular biology applications. These high-capacity rotors are designed to process more tubes in fewer runs, saving time while reducing energy and wear on the centrifuge.
“Clinical and life science researchers using a general purpose centrifuge are always looking to save time, space and money while increasing productivity,” said Maurizio Merli, global product director, centrifugation, for Thermo Fisher Scientific. “Our latest rotor innovations address researchers’ needs by allowing them to spin more samples in one run for increased production without surrendering space, performance or flexibility.”
The Thermo Scientific general purpose centrifuge line is designed for a wide range of clinical and life science applications, from cell culture to bioproduction to proteomics, food safety, pharmaceutical, stem cell, microbiology and genomics. The general purpose centrifuge floor models conserve valuable bench space with an almost 25% smaller footprint compared to refrigerated benchtop models and a working height of 79 cm, providing true ergonomic design for removing tubes and exchanging rotors.
The new rotor innovations in the general purpose centrifuge line offer a number of features and benefits:
• TX-1000 rotor: • Up to 40 X 50 mL conical tubes, 196 blood tubes or 24 microplates
• Advanced lubricant and corrosion resistant coating
• Dual-purpose large bucket design accepts adapters for tubes or microplates
• MicroClick 30 x 2 rotor: • High 30-place volume for 1.5/2.0 mL microtube and nucleic acid spin columns
• ClickSeal biocontainment lid for quick and easy sample access.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance